News
-
-
-
COMMUNIQUÉ DE PRESSE
aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024
aap Implantate AG reports 5.6% sales growth in Q1 2024, positive developments across all regions & progress in human clinical trial of antibacterial implant technology -
-
-
COMMUNIQUÉ DE PRESSE
aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights
aap Implantate AG successfully completes 10% capital increase at EUR 1.10, raising EUR 986,311.70 for human clinical trial of antibacterial implant technology -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: aap Implantate AG: aap postpones publication of the consolidated financial statements 2023 due to staff shortages
aap Implantate AG postpones the publication of the consolidated financial statements 2023 due to staff shortages. The Annual General Meeting may also be affected by this delay -